Drug intelligence / Profile preview

n-(2-hydroxyethyl)retinamide

Development stage
Preclinical
Lead developer
National Cancer Institute
Modality
Small Molecules
Administration
Oral, Intraperitoneal
01

Overview

n-(2-hydroxyethyl)retinamide is a synthetic derivative of retinoic acid belonging to the class of synthetic retinamides. Like other retinoids, it was primarily developed for *cancer chemoprevention* due to its reduced toxicity relative to natural retinoids while maintaining significant biological activity. Preclinical animal studies revealed that n-(2-hydroxyethyl)retinamide inhibits neoplastic transformation and impacts epithelial cell differentiation, probably through gene activation mechanisms, even though it has minimal measurable affinity for retinoid receptors and may act partly via slow hydrolysis to retinoic acid. It has not been developed or marketed for commercial pharmaceutical use, and limited evidence exists for its use in human clinical trials[1][2][5].

Other names
Retinamide n-(2-hydroxyethyl)-2-hydroxyethylretinamideretinoic acid 2-hydroxyethylamide
02

Targets

RBP4 (Retinol-binding protein 4)

Beyond the preview

Go deeper on n-(2-hydroxyethyl)retinamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on n-(2-hydroxyethyl)retinamide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call